APG-157 for advanced head and neck cancer
Treatments studied
Part of Cancer, Mouth & dental clinical trials.
This trial tests a new drug called APG-157 for people with advanced head and neck cancer that hasn't spread. It may be given before or instead of surgery, and the goal is to see if it helps shrink tumors or control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of head and neck cancer that is locally advanced (has grown into nearby tissues) but hasn't spread to distant organs.
- Your cancer is in the mouth (oral cavity) or the back of the throat (oropharynx).
- You have not received any treatment for this cancer yet.
- You are otherwise fit enough for surgery or, if not, you are eligible for chemotherapy plus radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether APG-157 can safely improve abnormal cells in the mouth (dysplasia) or early cancer-like changes (carcinoma in situ). You may be eligible if you have a visible, biopsy-proven lesion and can take oral medication while meeting blood and health requirements.
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
This study tests two experimental drugs for people with neuroblastoma or other solid tumors that have not responded to standard treatment. APG-115 is given alone or with APG-2575 to see if it can shrink tumors and help patients feel better.
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
This trial tests a new combination of two investigational drugs (adebrelimab and dalpiciclib) given before surgery for locally advanced head and neck cancer that is not linked to HPV. The goal is to see if these drugs can shrink the tumor and possibly improve outcomes.
This Phase 2 trial tests a drug strategy for people with locally advanced head and neck cancer linked to HPV status. It looks at “molecular residual disease” by measuring tumor DNA in blood and uses early response and tumor test results to see who may benefit.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.